Skip Navigation

Great Point Partners

Specialty Pharmaceuticals

Great Point Company Description Invested Status
APT Pharmaceuticals, Inc.
Burlingame, CA

APT Pharmaceuticals, Inc.
APT is a leading specialty pharmaceuticals business focusing on rare lung diseases. APT is developing Pulminiq, a proprietary formulation of inhaled cyclosporine, for prevention of chronic rejection and death in lung transplant patients. Pulminiq is entering a pivotal Phase 3 trial in approximately 150 patients at leading lung transplant centers worldwide. APT is also developing other pulmonary products. 2007 Acquired by MEI Pharma
Biodel, Inc.
Danbury, CT

View Web Site

Biodel, Inc.
Biodel's first product is a rapid acting injectable insulin called Viaject™. Viaject™ is designed to speed the delivery of insulin into the blood and will compete in the multi-billion dollar rapid acting insulin market. The Company has been financed with growth equity from Great Point Partners. 2006 IPO 2007

Back to Industry Segments